

# (12) UK Patent Application (19) GB (11) 2 356 197 (13) A

(43) Date of A Publication 16.05.2001

(21) Application No 0024805.4  
(22) Date of Filing 10.10.2000  
(30) Priority Data  
(31) 60158871 (32) 12.10.1999 (33) US

(71) Applicant(s)  
Merck & Co Inc  
(Incorporated In USA - New Jersey)  
P O Box 2000, 126 East Lincoln Avenue, Rahway,  
New Jersey 07065-0900, United States of America  
  
(72) Inventor(s)  
Wallace T Ashton  
Robert Mathvink  
Elizabeth M Naylor  
Emma R Parmee  
Ann E Weber  
  
(74) Agent and/or Address for Service  
I J Hiscock  
Merck & Co., Inc, European Patent Department,  
Terlings Park, Eastwick Road, HARLOW, Essex,  
CM20 2QR, United Kingdom

(51) INT CL<sup>7</sup>  
C07D 413/12 , A61K 31/426 31/427 31/4402 31/4427  
31/444 31/496 , C07D 213/56 277/30 // A61P 1/04  
3/04 3/06 3/10 9/10 11/06 13/08 27/06 ( C07D 413/12  
213/56 277:30 ) ( C07D 413/12 261:08 277:30 ) ( C07D  
413/12 237:08 277:30 )  
  
(52) UK CL (Edition S )  
C2C CAA  
U1S S1317 S1318 S1321 S2414 S2415 S2416 S2418  
  
(56) Documents Cited  
WO 99/20607 A1  
Chemical Abstract No 129:198012 & JP100218861A2  
(YAMANOUCHI PHARMACEUTICAL CO., LTD)  
  
(58) Field of Search  
UK CL (Edition R ) C2C  
ONLINE: CAS-ONLINE

(54) Abstract Title  
Amide derivatives as beta 3 agonists

(57) Amide derivatives are selective  $\beta_3$  adrenergic receptor agonists with very little  $\beta_1$  and  $\beta_2$  adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

GB 2 356 197 A